Posts

Tsingke Highlights AI-Driven CLDN18.2 Antibody Discovery at AIS 2026

on

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion to Expand ADC Oncology Pipeline

on

Enhertu Approved in the EU as First Tumor Agnostic HER2-Directed Therapy for Previously Treated HER2-Positive Metastatic Solid Tumors

on

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

on

Daiichi Sankyo's ADC Manufacturing Investments and Market Position

on

GSK CEO's 'Scientific Courage' Propels ADC Toward Phase 3 Trials

on

Gilead Continues Dealmaking Streak with $3.15B Tubulis Buy for ADCs

on

Sidewinder Therapeutics Announces $137 Million Series B Financing for Bispecific ADC Development

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Roche returns to Chinese biotech MediLink for another ADC pact

on

Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C

on

Spotlight On: Five key oncology stories to watch in 2026

on

Building the Next Generation of Biologics: Inside the Future of Protein Engineering

on

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

on

Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

on

Blackstone Pays Merck $700M to Fund Development of Antibody-Drug Conjugate

on

FDA Approves Syndax's First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

on

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

on